



Effects of Smoking on Serum Lecithin: Cholesterol Acyltransferase Activity

Corresponding Author:

Dr. K K Kshitiz,
Assistant Professor, Biochemistry LHMC, G Block Patel Nagar, 110067 - India

Submitting Author:

Dr. K K Kshitiz,
Assistant Professor, Biochemistry LHMC, G Block Patel Nagar , 110067 - India

Article ID: WMC004169

Article Type: Research articles

Submitted on: 30-Mar-2013, 08:03:17 PM GMT **Published on:** 01-Apr-2013, 06:09:44 AM GMT

Article URL: http://www.webmedcentral.com/article_view/4169

Subject Categories: CLINICAL BIOCHEMISTRY

Keywords: Smoking, Coronary Heart Disease, Lecithin: Cholesterol Acyltransferase

How to cite the article: Kshitiz K . Effects of Smoking on Serum Lecithin: Cholesterol Acyltransferase Activity . WebmedCentral CLINICAL BIOCHEMISTRY 2013;4(4):WMC004169

Copyright: This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC-BY\)](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Source(s) of Funding:

None

Competing Interests:

None

Effects of Smoking on Serum Lecithin: Cholesterol Acyltransferase Activity

Author(s): Kshitiz K

Abstract

Smoking is an established cardiovascular disease risk factor. But the mechanism how it causes cardiovascular risk is still not properly understood. This study was aimed to evaluate effects of smoking on lecithin:cholesterol acyltransferase (LCAT) activity, a key factor in the esterification of plasma cholesterol and reverse cholesterol transport. 30 male cigarette smokers and 30 male non-smokers were enrolled. Serum LCAT activity was determined as a function of the decrease of free cholesterol which is esterified during incubation at 37, as described by Hitz et al (15). Serum LCAT activity was lower in smokers, but the difference was statistically non-significant. So we got the idea that LCAT activity tended to be lower in smokers compared to nonsmokers and this adverse effect may lead to serious metabolic diseases like atherosclerosis.

Introduction

Cigarette smoking is the most common type of tobacco use. By 2030, if current trends continue, smoking will kill more than 9 million people annually(1). Smoking is considered as a major cardiovascular risk factor (2). There is a dose response relationship between the number of cigarettes smoked and cardiovascular morbidity and mortality (3). The mechanism by which cigarette smoking causes atherosclerosis remains obscure, but cigarette smoking has been found to alter the level of lipoproteins (4-8). Plasma lipoprotein abnormalities are said to be the underlying major risk factors and may even be essential for the common occurrence of atherosclerotic vascular diseases

The role of LCAT in atherosclerosis is not clearly established, studies have yielded conflicting results. Sethi et al. demonstrated that low lecithin-cholesterol acyltransferase (LCAT) activities and high pre- β 1-HDL concentrations are strong positive risk markers for ischemic heart disease and independent of HDL cholesterol.(9). Holleboom et al. showed that low plasma LCAT levels (reflecting low LCAT activity) are not associated with an increased risk of future CAD in

the general population(10). Other studies showed a positive association of LCAT levels with carotid atherosclerosis in patients with the metabolic syndrome as well as in control subjects, LCAT activity was reduced in patients with CAD and in patients with acute myocardial infarction. It can be reasoned that LCAT activity might be reduced in the acute phase of a myocardial infarction, but may normalize over time. We investigated the effects of smoking on the levels of LCAT activity in fasting blood from healthy smokers and nonsmokers, matched for age and body mass index (BMI).

Materials And Methods

The study was conducted on 30 healthy male cigarette smokers in an age group of 25-35 years and it was compared with 30 healthy age, diet and Body mass index (BMI) matched nonsmokers. Informed consent was obtained from all subjects. Only those persons were included in the study, who had no other existing diseases. Persons taking vitamin C or any other antioxidants were also not included in the study. Persons smoking 5 cigarettes or more per day continuously for a year were considered as smokers.

A detailed physical examination of the subjects of both groups was done. After 12 hrs overnight fasting, venous blood samples were drawn and subjected to laboratory investigations including blood glucose, blood urea, serum alkaline phosphatase, haemogram, lipid profile and LCAT activity.

The data between control and test groups was compared using unpaired student's t test. Correlation was determined by Pearson's correlation coefficient. A two-tailed p value less than 0.05 was considered to be statistically significant.

Results

Table 1

Showing clinical characteristics (Mean \pm SEM) in non-smokers and smokers.

See Illustration 1

Table 2

LCAT activity between smokers and non-smokers.

See Illustration 2

Table 3.

Serum LCAT activity, based on exposure to cigarette smoke.

See Illustration 3

The study groups comprised of 30 male smokers (mean age \pm SD, 31.20 ± 1.33) and 30 male non-smokers (31.23 ± 1.35). The body mass indexes were 20.96 ± 0.60 and 20.99 ± 0.60 kg/m² in smokers and non-smokers, respectively (Table 1). Serum LCAT activity was lower in smokers than in non-smokers, although this difference was statistically non significant (Table 2).

Discussion

In the study, the two groups of subjects (smokers and non-smokers) were of comparable sex, age, BMI and diet. They were non-diabetic, non-alcoholic, normotensive subjects, mostly (70%) belonging to middle socioeconomic status. There are several studies showing lower serum LCAT concentrations or activities in smokers compared to non-smokers (11). Haffner et al. reported a negative correlation between smoking and LCAT mass (12). The positive correlation between LCAT concentration and TC and LDL-C was also reported in these studies (11-13). These findings are in accordance with the suggestion that LCAT plays an important role in the reverse transport of cholesterol. In addition to in vivo studies, in vitro studies have shown that cigarette smoke inhibited LCAT activity (14). In another study, it was reported that rats given nicotine had lower LCAT activity (15). However, in several studies, LCAT activity was found not to be different in smokers and non-smokers (14, 16). In our study, serum LCAT activity was found to be 19.13% lower in smokers than in non-smokers, but this difference was not statistically significant. LCAT activity tended to be lower in smokers compared to non-smokers. So, it may be considered that the reverse cholesterol transport can be diminished and cholesterol can accumulate in the peripheral tissues, more in the smokers than non-smokers.

References

1. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EFM. Systemic Effects of Smoking. *Chest* ; 131:1557-156,(2007)
2. Ghannem H, Harrabi I, Ben AA, Gaha R, Trabelsi L. Smoking habits and cardiovascular risk factors among adolescents in Sousse, Tunisia. *Arch Public Health* ; 61: 151-160,(2003)
3. Wynder EL, Harris RE, Haley NJ. Population screening for plasma cholesterol. Community based results from Connecticut. *Am Heart J* ;117:649- 56, (1989).
4. Mammas IO, Bertias GK, Linardakis M, Tzanakis NE, Labadarios DN, Kafatos AG. Cigarette smoking , alcohol consumption, and serum lipid profile among medical students in Greece. *European Journal of Public Health* ; 13: 278–282, (2003)
5. Neki NS. Lipid profile in chronic smokers-A clinical Study. *JACM* ; 3:51- 4,(2002).
6. Yasue H, Hirai N, Mizuno Y, Harada E, Itoh T, Yoshimura M, Kugiyama K, Ogawa H. Low grade inflammation, thrombogenicity, and atherogenic lipid profile in cigarette smokers. *Circulation*;70(1):8-13, (2006)
7. Guedes DP, Guedes JE, Barbosa DS, de Oliveira JA. Tobacco use and plasma lipid lipoprotein profile in adolescents .*Rev Assoc Med Bras* ;53(1):59-63, (2007)
8. Wakabayashi I. Associations of alcohol drinking and cigarette smoking with serum lipid levels in healthy middleaged men .*Alcohol Alcohol* ;43(3):274-80, (2008)
9. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Sethi AA et al., *Clin Chem* 2010 Jul;56(7):1128-1137.
10. Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study. Holleboom AG et al., *J Lipid Res.* 2010 Feb;51(2):416-421.
11. Albers JJ, Bergelin RO, Adolphson JL, Wahl PW : Population-based reference values for lecithin-cholesterol acyltransferase (LCAT). *Atherosclerosis* 43 (2-3) : 369-379, 1982
12. Haffner SM, Applebaum-Bowden D, Wahl PW : Epidemiological correlates of high density lipoprotein subfractions, apolipoproteins A-I, A-II, and D, and lecithin cholesterol acyltransferase. Effects of smoking, alcohol, and adiposity. *Arteriosclerosis* 5 : 169-177, 1985
13. Rönnemaa T, Viikari J, Marniemi J. Lecithin : cholesterol acyltransferase activity in children and young adults. *Atherosclerosis* 77 : 7-13, 1989
14. McCall MR, van den Berg JJ, Kuypers FA, Tribble DL, Krauss RM, Knoff LJ : Modification of LCAT activity and HDL structure. New links between cigarette smoke and coronary heart disease risk. *Arterioscler Thromb* 14 (2) :248-253, 1994
15. Latha MS, Vijayammal PL, Kurup PA : Effect of

nicotine administration on lipid metabolism in rats.

Indian J Med Res 98 : 44-49, 1993

16. Dullaart RP, Hoogenberg K, Dikkeschei BD, Van Tol A : Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. *Arterioscler Thromb* 14 (10) : 1581-1585, 1994

Illustrations

Illustration 1

Showing clinical characteristics (Mean \bar{X} , $\hat{\sigma}$ \pm SEM) in non-smokers and smokers.

Parameter	Non –smokers (n= 20)	Smokers (n= 60)
Age	31.20 \pm 1.33	31.23 \pm 1.35
Body weight (kg)	58.90 \pm 1.91	59.20 \pm 1.91
Height (cm)	167.40 \pm 1.1	167.90 \pm 0.90 B
BMI (kg/m ²)	20.96 \pm 0.60	20.99 \pm 0.60

All parameters were not significantly different between groups.

Illustration 2

LCAT activity between smokers and non-smokers.

Parameter	Non smoker	Smoker
LCAT($\mu\text{mol.L}^{-1}.\text{h}^{-1}$)	80.30 \pm 54.90	65.00 \pm 48.80

LCAT activity was not significantly different between groups.

Illustration 3

Serum LCAT activity, based on exposure to cigarette smoke.

	Brinkmann index < 300	Brinkmann index > 300	P
	N=30	N=30	
LCAT activity ($\mu\text{mol.L}^{-1}.\text{h}^{-1}$)	78.4 \pm 48.00	57.2 \pm 43.67	>0.05

Disclaimer

This article has been downloaded from WebmedCentral. With our unique author driven post publication peer review, contents posted on this web portal do not undergo any prepublication peer or editorial review. It is completely the responsibility of the authors to ensure not only scientific and ethical standards of the manuscript but also its grammatical accuracy. Authors must ensure that they obtain all the necessary permissions before submitting any information that requires obtaining a consent or approval from a third party. Authors should also ensure not to submit any information which they do not have the copyright of or of which they have transferred the copyrights to a third party.

Contents on WebmedCentral are purely for biomedical researchers and scientists. They are not meant to cater to the needs of an individual patient. The web portal or any content(s) therein is neither designed to support, nor replace, the relationship that exists between a patient/site visitor and his/her physician. Your use of the WebmedCentral site and its contents is entirely at your own risk. We do not take any responsibility for any harm that you may suffer or inflict on a third person by following the contents of this website.